Veracyte | VCYT - Cost Of Sales


Veracyte reported $38.49M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Agilent USD 845M 7M Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
Bruker USD 443.6M 84.4M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Illumina USD 370M 30M Mar/2026
Intrexon USD 1.01M 344K Jun/2024
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Laboratory Of America USD 2.6B 4.2M Mar/2026
Ligand Pharmaceuticals USD 11.37M 8.38M Mar/2026
Myriad Genetics USD 63M 1.1M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Siemens EUR 12.07B 565M Mar/2026
Sonic Healthcare AUD 751.66M 801.13M Dec/2024
Thermo Fisher Scientific USD 6.96B 620M Mar/2026
Veracyte USD 38.49M 794K Mar/2026
Waters USD 725M 350.06M Mar/2026